Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

Key PointsViking is testing weight loss drug candidates in late-stage trials.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

More from Friday 25 September →